Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Letrozole + Ribociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Letrozole||Femara||Letrozol||Aromatase Inhibitor 3||Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov).|
|Ribociclib||Kisqali||LEE011||CDK4/6 Inhibitor 9||Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RB1 H483Y||Her2-receptor negative breast cancer||predicted - resistant||Letrozole + Ribociclib||Case Reports/Case Series||Actionable||In a clinical case study, RB1 H48Y was identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940).||29236940|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01872260||Phase I||Alpelisib + Letrozole Alpelisib + Letrozole + Ribociclib Letrozole + Ribociclib||Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer||Active, not recruiting|
|NCT03613220||Phase II||Letrozole + Ribociclib||CompLEEment-1 Canadian Correlative Sub-Study (LEEomic)||Recruiting|
|NCT02712723||Phase II||Letrozole + Ribociclib||Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer||Active, not recruiting|
|NCT01958021||Phase III||Letrozole + Ribociclib Letrozole||Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) (MONALEESA-2)||Active, not recruiting|
|NCT03822468||Phase II||Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Letrozole + Ribociclib||Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PMR)||Recruiting|
|NCT03673124||Phase II||Letrozole + Ribociclib||Ribociclib and Letrozole Treatment in Ovarian Cancer||Recruiting|
|NCT02657928||Phase II||Letrozole + Ribociclib||Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer||Active, not recruiting|
|NCT02941926||Phase III||Letrozole + Ribociclib Leuprolide Goserelin||Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC||Active, not recruiting|
|NCT04256941||Phase II||Abemaciclib + Fulvestrant Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Anastrozole||Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study||Recruiting|